Case Report
Copyright ©2011 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. May 14, 2011; 17(18): 2353-2355
Published online May 14, 2011. doi: 10.3748/wjg.v17.i18.2353
Transarterial injection of H101 in combination with chemoembolization overcomes recurrent hepatocellular carcinoma
Qing He, Yang Liu, Qing Zou, Yong-Song Guan
Qing He, Yang Liu, Qing Zou, Yong-Song Guan, Department of Oncology, West China Hospital of Sichuan University, Chengdu 610041, Sichuan Province, China
Author contributions: He Q and Guan YS contributed equally to this work; Liu Y and Zou Q analyzed the data.
Correspondence to: Dr. Yong-Song Guan, Department of Oncology, West China Hospital of Sichuan University, Chengdu 610041, Sichuan Province, China. yongsongguan@yahoo.com
Telephone: +86-28-85421008 Fax: +86-28-85538359
Received: December 9, 2010
Revised: February 15, 2011
Accepted: February 22, 2011
Published online: May 14, 2011
Abstract

Transcatheter arterial chemoembolization (TACE) has become the standard treatment modality for unresectable hepatocellular carcinoma (HCC). Nonetheless, the clinical outcomes in patients with unresectable HCC are often unsatisfactory, especially in those with recurrent HCC. H101, an E1B gene deleted adenovirus, is known to have a significant antitumor activity. In addition, local injection of H101 can enhance the effect of antitumor therapies (chemotherapy and radiotherapy). Transarterial H101 gene injection in combination with TACE may help to control refractory and recurrent HCC. In this study, we report a 55-year-old patient with recurrent HCC which was treated with transarterial injection of H101 in combination with TACE, leading to a good clinical prognosis of the patient.

Keywords: Hepatocellular carcinoma, H101, Transcatheter arterial chemoembolization, Therapy